<DOC>
	<DOCNO>NCT01835587</DOCNO>
	<brief_summary>The purpose study determine maximal tolerate dose schedule CC-486 ( also know oral Azacitidine ) patient AML MDS allogeneic HSCT . Allogeneic hematopoietic stem cell transplantation ( HSCT ) frequently use Acute Myloid leukemia ( AML ) Myelodysplastic Syndromes ( MDS ) potential curative therapy . However , disease recurrence/relapse graft-versus-host disease ( GVHD ) remain principal cause fatal complication transplantation . Azacitidine significant activity MDS AML . Azacitidine also demonstrate immunomodulatory activity AML patient allogeneic HSCT . An oral formulation Azacitidine provide convenient route administration opportunity deliver drug prolong schedule .</brief_summary>
	<brief_title>Safety Study Oral Azacitidine ( CC-486 ) Maintenance Therapy After Allogeneic Hematopoietic Stem Cell Transplantation Subjects With Acute Myeloid Leukemia Myelodysplastic Syndromes</brief_title>
	<detailed_description>This open-label , multicenter study oral Azacitidine MDS AML patient undergone allogeneic HSCT . The study consist three phase : Screening , Treatment Follow-up . During Screening phase , take place within 4 week start oral Azacitidine , study doctor test see patient suitable study . The patient meeting protocol-specified entry criterion enter Treatment phase assign receive oral Azacitidine 200 300 mg daily ( QD ) first 7 14 day 28-day cycle . The dose group 200 mg QD Days 1 7 evaluate first ( ie , Cohort 1 ) . In event unacceptable toxicity occur Cohort 1 , oral Azacitidine may evaluate low dose level ( eg , 150 mg ) . If dose regimen confirm safe Cohort 1 , cohort evaluate sequentially . During treatment phase , subject monitor closely safety tolerability . Dosing interruption delay , dose schedule reduction , intra-subject dose/schedule escalation re-escalation may occur basis protocol-specified dose adjustment guideline . Safety monitor throughout study predetermine interval clinically indicate vital sign , physical examination , performance status , laboratory test evaluation adverse event . The patient continue receive study treatment 12 month provide benefit study treatment protocol-specified criterion meet . However , patient may receive study treatment le 12 month due adverse event , disease recurrence progression . When study treatment discontinue , patient receive least one dose oral Azacitidine ask see study doctor Treatment Discontinuation visit . Thereafter , patient discontinue study treatment enter Follow-up phase safety survival follow .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<criteria>Histologically confirm ( Myelodysplastic Syndromes ) MDS Acute Myeloid Leukemia ( AML ) undergo allogeneic hematopoietic stem cell transplantation ( HSCT ) either peripheral blood bone marrow source hematopoietic stem cell At time allogeneic HSCT : No prior allogeneic HSCT ; No 1 antigen mismatch Human Leukocyte Antigen ( HLA ) A , B , C , DRB1 DQB1 locus either relate unrelated donor ; Bone marrow blast &lt; 20 % MDS ≤ 10 % AML ; Peripheral blood blast ≤ 5 % Be able start study therapy 42 84 day follow allogeneic HSCT Post transplant bone marrow blast count ≤ 5 % confirm within 21 day prior start study therapy Adequate engraftment within 14 day prior start study therapy : Absolute Neutrophil count ( ANC ) ≥ 1.0 x 109/L without daily use myeloid growth factor ; Platelet count 75 x 109/L without platelet transfusion within one week . Adequate organ function : Serum aspartate transaminase ( AST ) alanine transaminase ( ALT ) &lt; 3 x upper limit normal ( ULN ) Serum bilirubin &lt; 2 x ULN Serum creatinine &lt; 2 x ULN Adequate coagulation ( Prothrombin time [ PT ] ≤ 15 second , Partial thromboplastin time ( PTT ) ≤ 40 second , and/or International normalized ratio [ INR ] ≤ 1.5 ) Have negative serum pregnancy test ( sensitivity least 25 mIU/mL screen ) . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 , 1 2 Must agree follow protocolspecified pregnancy precaution Use follow transplantation prior start oral Azacitidine : Chemotherapeutic agent chemotherapy Investigational agents/therapies Azacitidine , decitabine demethylating agent Lenalidomide , thalidomide pomalidomide Active Graftversushost disease ( GVHD ) grade II high Any evidence gastrointestinal ( GI ) GVHD Concurrent use corticosteroid equivalent prednisone dose &gt; 0.5 mg/kg Known active viral infection Human Immunodeficiency Virus ( HIV ) , Hepatitis B Virus ( HBV ) Hepatitis C Virus ( HCV ) Active uncontrolled systemic fungal , bacterial viral infection Presence malignancy , MDS AML , within previous 12 month Significant active cardiac disease within previous 6 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Acute myeloid leukemia ,</keyword>
	<keyword>myelodysplastic syndrome ,</keyword>
	<keyword>CC-486 , oral Azacitidine ,</keyword>
	<keyword>transplantation ,</keyword>
	<keyword>allogeneic ,</keyword>
	<keyword>HSCT .</keyword>
</DOC>